Novo Nordisk’s Wegovy pill launch draws new wave of patients to GLP-1s

After years of attempting to shed some pounds “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” 

Zuckerman, a 32-year-old information analyst based mostly in Washington, D.C., mentioned she misplaced 90 kilos in school and spent years biking via nutritionists, remedy and strict routines — solely to discover herself at her heaviest after the pandemic, at 270 kilos. 

Zuckerman mentioned GLP-1 injections have been out of the query, as a result of she’s afraid of needles. But when the primary GLP-1 pill for weight problems grew to become out there in early January, Zuckerman known as her physician instantly, she mentioned. 

Almost a month after beginning Novo Nordisk‘s new Wegovy pill shortly after it launched, she mentioned, she had misplaced round 11 kilos.

Zuckerman is amongst tens of 1000’s of patients who drove an explosive demand for prescriptions for Novo’s pill simply three months into its launch. Many of them share a standard thread: They had lengthy held off on utilizing GLP-1s due to obstacles resembling excessive out-of-pocket prices for injections or a concern of needles.

That’s one of the earliest takeaways from the rollout: Novo’s pill seems to be increasing the weight problems remedy market, largely drawing in new patients reasonably than changing current ones from injections. CNBC spoke with 5 U.S. patients who not too long ago began the pill following its launch, all of whom mentioned they haven’t beforehand taken branded GLP-1 injections.

But it is early days for the pill. Many patients have but to attain greater doses of the drug, and their experiences differ. It will take extra time to decide how efficient the pill is in supporting patients’ long-term weight reduction journeys, whether or not it helps maintain customers on GLP-1s for longer than injections do and whether or not demand for Novo’s product will maintain within the face of contemporary competitors from Eli Lilly. 

Novo has a head begin within the pill enviornment over Lilly, which simply received U.S. approval of its personal GLP-1 drug for weight problems final week. Analysts beforehand instructed CNBC they nonetheless count on that rival pill, known as Foundayo, to seize a phase of the market, partly as a result of it lacks the dietary restrictions that include Novo’s oral drug. 

Still, the Wegovy pill seems to have had probably the most explosive launch of a GLP-1 product but. The newest quantity that Novo disclosed in February is that greater than 600,000 prescriptions had been written since its launch, together with for greater than 3,000 patients within the first week.

Analysts at BMO Capital Markets attributed some of the early uptake to an “attractive” entry value of $149 per thirty days and its connection to the well-known Wegovy model. The pill carries one of the bottom money costs for a GLP-1 remedy, starting from $149 to $299 per thirty days, relying on the dose.

Even so, the pill’s launch has executed little to increase Novo’s inventory value, because the Danish drugmaker is struggling to win again market share from Lilly within the broader weight problems house and persuade traders that its drug pipeline can assist it develop past its current merchandise.

Novo is predicted to report first-quarter gross sales, which can embrace the pill for the primary time, in May. But gross sales of the general Wegovy portfolio are anticipated to improve from $13.5 billion in 2026 to $18.9 billion in 2031, with the pill contributing $2.76 billion, in accordance to a March GlobalData report.  

The Wegovy pill is attracting patients with a concern of needles, which is estimated to affect up to 25% of U.S. adults. But the drug can be an alternate for many who have had problem accessing branded GLP-1 injections or different drugs. 

“There are a handful of patients that don’t want to be stung by the needle in the case of a vial and syringe, or stung by the price,” Jamey Millar, Novo’s head of U.S. operations, instructed CNBC in an interview final week. “We’re appealing to both.” 

Dr. Eduardo Grunvald, medical director of the UC San Diego Health Center for Advanced Weight Management, mentioned the principle motive he is prescribed the Wegovy pill to some patients is value, since its money costs are barely decrease than these of injections. But Grunvald mentioned general, weight problems drugs specialists like him will nonetheless be inclined to prescribe injections over oral medication, partly as a result of the photographs are simpler. 

Cost was a deciding issue for Amy Sawyer-Williams, who works at a theater firm in Raleigh, North Carolina, and has gestational diabetes. In 2023, a number of years after her son was born, she mentioned, she started creating prediabetes and met the factors for weight problems. She mentioned she would have began utilizing GLP-1 injections sooner, however her insurance coverage wouldn’t cowl them for her. 

That was lengthy earlier than Novo and Lilly slashed the money costs of their weight problems and diabetes injections. 

The checklist costs of their photographs are roughly $1,000 per thirty days earlier than insurance coverage and different rebates, or reductions for cash-paying patients — a sum that has lengthy prevented many others from beginning and staying on remedy. Novo has committed to cutting the monthly list prices of its medication within the U.S. by up to 50%, however that change will not go into impact till 2027. 

High costs additionally shut Sawyer-Williams out from taking the branded weight administration remedy Contrave, pushing her to mix two generic drugs to mimic the drug’s results, she mentioned. But earlier this yr, she mentioned, her endocrinologist advisable the Wegovy pill, partly due to its decrease $149 per thirty days pricing for the beginning dose. 

Sawyer-Williams grew to become the primary affected person at her physician’s follow and native Walgreens to take the pill, beginning in mid-January, she mentioned. 

Some Wegovy pill customers are patients who wished to swap over from injections, mentioned Dr. Heather Hofflich, a doctor and endocrinologist at UCSD Health. She mentioned she’s prescribed the pill for some individuals whose insurance coverage stopped masking the injections however who need to proceed remedy. 

Hofflich mentioned she has additionally prescribed the oral drug to patients who misplaced weight initially on a shot however are actually attempting the pill to preserve that progress. 

While it is nonetheless early, some patients mentioned they’re already benefiting from taking Novo’s drug. 

Zuckerman was initially skeptical of how efficient the product can be, as a result of it is an oral remedy. But, she mentioned, “I swear I felt the impact on the first day,” notably decreased urge for food and disinterest in meals. 

“Things that used to give me enjoyment, or things I used to binge on, they just don’t taste as good anymore, and I just don’t see the point in eating them, honestly,” Zuckerman mentioned, itemizing espresso, cheese, bread and fries, amongst different meals and drinks. 

She mentioned she handled nausea — a standard facet impact of the GLP-1 class — however that grew to become extra manageable after the primary two weeks on the pill.

Zuckerman additionally mentioned what issues greater than the burden loss or meals urges is how she feels: “My clothes are looser, I have more energy, I genuinely feel better.” 

Cherie Marcus, 72, a retired material designer and theater editor based mostly in Brooklyn, mentioned she’s additionally seen gradual progress — even on the bottom 1.5-milligram dose of the drug. She mentioned that over the past 30 years, after her daughter was born, she’s gained weight and seen her hemoglobin A1c — a key measure of blood sugar ranges — creep up. 

Marcus mentioned she began the pill on Jan. 24, and has misplaced a few pound per week whereas taking the bottom dose for seven weeks. Patients sometimes improve their dosage after a month, however Marcus mentioned she’s nonetheless taking the bottom energy as of early April. 

But her weight has “leveled off” over the previous few weeks, she mentioned, so she is going to probably transfer to the next dose if she stops dropping pounds completely. Marcus sees herself taking the pill long run, with a objective of shedding round 30 kilos. 

Novo’s Millar final week mentioned some patients could begin on decrease doses and “be perfectly fine with that,” hitting their very own private objectives for weight reduction. But the corporate is monitoring what number of patients improve to greater doses of the drug, notably the 9-mg and 25-mg variations.  

Courtney Kim, a stay-at-home mother based mostly in Pittsburgh, is among the many patients taking the Wegovy pill who’ve but to expertise notable unwanted effects. 

While she does not qualify as overweight, Kim mentioned, the “weight would just not come off” after she had her three youngsters. She began the pill round mid-February after struggling to shed some pounds with the use of different prescription drugs and dietary supplements, she mentioned. 

Kim began at a weight of roughly 158 kilos and has up to now misplaced practically 7 kilos on the pill, she mentioned. She not too long ago began the 4-mg dose of the drug. 

“It’s actually working, and I’m shocked that the weight is actually like coming off and staying off,” Kim mentioned. “So far I’ve had a positive experience.”

The early expertise with the pill hasn’t been easy for everybody. UCSD’s Hofflich mentioned she had one affected person who couldn’t tolerate the pill due to its gastrointestinal unwanted effects, which is a standard difficulty with the injections, as nicely. 

Another affected person had to swap to an injection as a result of the pill’s dietary restrictions — which contain taking it with a small quantity of water and ready half-hour earlier than consuming or consuming — didn’t match into their way of life, Hofflich mentioned. Two patients who have not seen progress on greater doses of the pill are switching to injections, she mentioned. 

Hofflich mentioned different patients who have not seen progress on decrease doses are beginning to take greater doses to see if that can make a distinction. 

That features a affected person based mostly in New Hampshire named Amy, who mentioned she started taking the Wegovy pill in early February. She requested CNBC not to use her final identify, for privateness causes.

Amy mentioned she initially thought of a branded GLP-1 remedy two years in the past after her weight crept up to 190 kilos, however her physician mentioned her insurance coverage would not cowl it. Amy then turned to cheaper, unapproved compounded variations of GLP-1s for a yr and misplaced 30 kilos earlier than stopping in November. 

She mentioned the 2 lowest doses of the Wegovy pill — 1.5 mg and 4 mg — “did absolutely nothing for me” over two months. 

Novo’s money reductions allowed Amy to pay roughly $300 whole for a month’s price of every dose, however she mentioned she feels “frustrated” that she nonetheless feels hungry and has observed no modifications aside from unwanted effects together with constipation. Amy mentioned her weight is “hovering” round 170 kilos.

“It just kind of felt like a waste of time,” she mentioned. 

Amy mentioned she plans to begin the 9-mg dose of the pill quickly, hoping that she’ll start to see the advantages of remedy. She mentioned if that does not work, she’ll talk about along with her physician whether or not to strive the very best dose, 25 mg, or probably flip again to compounded GLP-1s. 

Meanwhile, Sawyer-Williams is restarting the bottom dose of the pill after pausing the drug due to gastrointestinal unwanted effects. She mentioned she was nervous about beginning the pill, as a result of she’s at all times had a delicate abdomen. 

During her first three weeks on the 1.5-mg dose of the oral drug, she didn’t discover any weight reduction, however skilled nausea if she did not eat, Sawyer-Williams mentioned. She began to really feel much less all in favour of meals by her fourth week, she mentioned, however started taking the following dose, 4 mg, shortly after.  

On the seventh day of taking that dose, Sawyer-Williams mentioned, she skilled “the worst” nausea, vomiting and dehydration, which induced her to cease remedy. 

“I wish I had just stayed on the 1.5” dose, she mentioned. “I was really, really sick. Even when I quit the pill, I just couldn’t keep down water.”

Sawyer-Williams began at a weight of 177 kilos and misplaced 5 kilos general after taking the drug, she mentioned. She’s been off remedy for a number of weeks, however began the bottom dose of the pill as of early April with new habits, together with staying hydrated and beginning to carry weights, she mentioned.

“We’re going to just have to hope that it’s enough to help me,” she mentioned, referring to the bottom dose. 

Dr. Andrea Traina, Novo’s weight problems medical director, advisable that patients who’re fighting unwanted effects speak to their health-care supplier about methods to mitigate them. For instance, she mentioned some individuals could profit from staying on a decrease dose till they tolerate the drug higher earlier than rising to the next dosage.

“Treating obesity, just like most chronic diseases, is kind of a marathon, not a sprint,” Traina mentioned in an interview. “So adding an extra month or two to help with tolerability upfront can help with kind of long-term success.”

Several questions stay in regards to the long-term use of the pill, particularly on greater doses, and it is probably not the most effective weight problems remedy for each affected person, consultants mentioned. 

Traina mentioned every affected person has a person response, and so they could reply nicely above or nicely under common in phrases of weight reduction and unwanted effects. That will be tied to their genetics, atmosphere or dietary habits, and experiences can differ barely throughout sure populations and age teams, she mentioned.

“It’s very tough to know why one patient’s responding to something and another isn’t,” Traina mentioned, including that it is “one of the many benefits of having multiple treatment options available.”

Having an oral choice at decrease money costs that “can be attainable for a larger population is a very good thing, to help us cure or alleviate this chronic disease state,” mentioned UCSD’s Hofflich. 

She mentioned within the coming months, notably with the rollout of Lilly’s new drug, “we’ll have many more stories and outcomes” of capsules to consider, permitting for clearer comparisons between the 2 capsules in addition to injections.

Patients resembling Zuckerman could provide an early glimpse of those that stand to profit most from the pill — and the instances the place it resonates.

“I was in this boat of seeing the pill as cheating and feeling like I had to lose the weight the hard way,” she mentioned. “But that doesn’t work for everybody, and eventually I got to the point where I was like, do I want to be stubborn and try to do this the ‘right way,’ or do I want to die from being obese?”

“Jumping on the opportunity to the pill at this stage in my life was the right decision,” Zuckerman mentioned.